In a large real-world analysis across three U.S. healthcare databases, semaglutide and tirzepatide showed cardiovascular benefits consistent with randomized trials. Semaglutide lowered heart attack and stroke risk versus sitagliptin, while tirzepatide performed comparably to dulaglutide and semaglutide over one year.
Diabetes drugs semaglutide and tirzepatide show real-world heart benefits
- Thread starter Educator
- Start date